In a previous work, the pharmacokinetics of oral HLZ were found to be dependent on the NAT2 genotype during pregnancy (Han et al., 2019), and SA status was shown to be associated with clinical blood pressure and 24-h blood pressure after HLZ treatment in patients with resistant hypertension (Garces-Eisele et al., 2014). Here, NAT2 is linked to Hypertension resistant to conventional therapy.